Characteristics Associated with Upper-Range Doses of Beta-Blockers and Angiotensin-Renin Inhibitors in Reduced Ejection Fraction.

Autor:	Itzhaki Ben Zadok O; Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Murninkas D; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Tel Aviv-Jaffa District, Clalit Health Services, Tel Aviv, Israel., Iakobishvili Z; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Tel Aviv-Jaffa District, Clalit Health Services, Tel Aviv, Israel., Jino H; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Tel Aviv-Jaffa District, Clalit Health Services, Tel Aviv, Israel., Yohananov E; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Tel Aviv-Jaffa District, Clalit Health Services, Tel Aviv, Israel., Birkenfeld S; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Tel Aviv-Jaffa District, Clalit Health Services, Tel Aviv, Israel., Hasdai D; Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Jazyk:	angličtina
Zdroj:	The Israel Medical Association journal : IMAJ [Isr Med Assoc J] 2020 Jul; Vol. 22 (7), pp. 441-445.
Abstrakt:	Background: Heart failure (HF) patients with reduced ejection fraction (HFrEF) are frequently treated with sub-optimal doses of angiotensin converting enzyme-inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), and beta blockers (BBs). Objectives: To determine factors associated with attaining upper-range doses in patients with HFrEF. Methods: We examined treatment in patients with left ventricular ejection fraction (LVEF) ≤ 40% in a community-based, dedicated heart-failure clinic. Upper-range doses were defined as ≥ 75% of target recommended doses by heart failure society guidelines. Results: The majority of the 215 patients were men (82%); median age at presentation 73 years (interquartile range [IQR] 65-78) and LVEF of 30% (IQR 25-35%). Following the up-titration program, 41% and 35% of patients achieved upper-range doses of ACE-Is/ARBs and BBs, respectively. Higher body mass index (BMI) was the only parameter found to be associated with achieving upper-range doses of ACE-I/ARBs (odds ratio [OR] 1.13, 95% confidence interval [95%CI] 1.05-1.22, P = 0.001). More patients achieved this target as BMI increased, with a sharp decline in the highest obesity category (BMI ≥ 40 m2/kg). Attaining upper-range doses of BBs was associated with pre-existing diabetes mellitus (DM) (OR 2.6, 95%CI 1.34-5.19, P = 0.005); women were associated with attaining lower BBs doses (OR 0.34, 95%CI 0.13-0.90, P = 0.031). Conclusions: Achieving upper-range doses of ACE-Is/ARBs and BBs in HFrEF outpatients in a treatment up-titration program were associated with greater BMI and DM, respectively. These findings may serve as benchmarks for up-titration programs.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu